Iambic Therapeutics CMO reports 40,459-share holding

One option had 25% vest on January 31, 2025, with 1/48th vesting monthly thereafter; the other vests in 48 equal monthly installments beginning March 23, 2026.

Rhea-AI Filing Summary

Iambic Therapeutics, Inc. Chief Medical Officer Neil Josephson reported direct holdings as of October 14, 2026: 40,459 common shares and two employee stock option positions covering 175,533 and 57,048 underlying common shares. The options have exercise prices of $4.95 and $8.73 per share and expire February 16, 2034, and March 3, 2036, respectively.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Josephson Neil

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (right to buy) F1	--	--	--
holding	Employee Stock Option (right to buy) F2	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 232,581 contracts (Direct); Common Stock — 40,459 shares (Direct)

Footnotes (2)

1. F1. An option to purchase 215,992 shares was granted on February 16, 2024 and was exercised in part prior to the date on which the reporting person became subject to Section 16. Twenty-five percent of the shares subject to the option vested on January 31, 2025 and 1/48th of the shares vest monthly thereafter.
2. F2. The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026.

Key Figures

Direct common shares: 40,459 shares Underlying common shares: 175,533 shares Exercise price: $4.95 per share +5 more

8 metrics

Direct common shares 40,459 shares Reported as of October 14, 2026.

Underlying common shares 175,533 shares Direct employee stock option; expires February 16, 2034.

Exercise price $4.95 per share Employee stock option covering 175,533 underlying common shares.

Option expiration February 16, 2034 Direct employee stock option covering 175,533 underlying common shares.

Underlying common shares 57,048 shares Direct employee stock option; expires March 3, 2036.

Exercise price $8.73 per share Employee stock option covering 57,048 underlying common shares.

Option expiration March 3, 2036 Direct employee stock option covering 57,048 underlying common shares.

Original option grant 215,992 shares Granted February 16, 2024; exercised in part before Josephson became subject to Section 16.

Key Terms

Employee Stock Option (right to buy), exercise price, vested, Section 16

4 terms

Employee Stock Option (right to buy) technical

"Employee Stock Option (right to buy)"

exercise price financial

"exercise price of $4.9500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"Twenty-five percent of the shares subject to the option vested"

Section 16 regulatory

"became subject to Section 16"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IAM shares and options did Neil Josephson report?

Neil Josephson reported 40,459 directly held common shares, plus employee stock options covering 175,533 and 57,048 underlying common shares. Their exercise prices are $4.95 and $8.73 per share, respectively.

What are the vesting schedules for Neil Josephson's IAM options?

The $4.95 option was granted for 215,992 shares on February 16, 2024, and was exercised in part before Josephson became subject to Section 16. Twenty-five percent vested on January 31, 2025, with 1/48th vesting monthly thereafter; the other option vests in 48 equal monthly installments beginning March 23, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 08:46 PM EDT Accepted by SEC EDGAR 10/14/2026 - 06:34 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Josephson Neil

(Last) (First) (Middle)

C/O IAMBIC THERAPEUTICS, INC.

5627 OBERLIN DRIVE, SUITE 120

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/14/2026

3. Issuer Name and Ticker or Trading Symbol
Iambic Therapeutics, Inc. [ IAM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	40,459	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(1)	02/16/2034	Common Stock	175,533	$4.95	D
Employee Stock Option (right to buy)	(2)	03/03/2036	Common Stock	57,048	$8.73	D

Explanation of Responses:

1. An option to purchase 215,992 shares was granted on February 16, 2024 and was exercised in part prior to the date on which the reporting person became subject to Section 16. Twenty-five percent of the shares subject to the option vested on January 31, 2025 and 1/48th of the shares vest monthly thereafter.

2. The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ /s/ Sunny Chang, by power of attorney	10/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)